Oral Modified-Release Tranexamic Acid for Heavy Menstrual Bleeding

OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety profile of an oral modified-release (MR) formulation of tranexamic acid. DATA SOURCES: Literature was accessed through MEDLINE (1966-July 2012), Iowa Drug Information Service (1997-July 2012), and bibliographies of pertinent articles. Search terms included tranexamic acid, Lysteda, menorrhagia, menstrual blood loss, and heavy menstrual bleeding. STUDY SELECTION AND DATA EXTRACTION: All available English-language abstracts and human studies were identified for review. Data provided by the manufacturer and the Food and Drug Administration were also evaluated. Efficacy was evaluated in 2 clinical trials, change in quality of life was evaluated in 3 clinical trials, and safety was evaluated in 4 clinical trials. DATA SYNTHESIS: Tranexamic acid is a synthetic lysine analogue with antifibrinolytic activity. It interferes with the binding of plasminogen to fibrin, resulting in enhanced fibrin clot integrity. A novel MR formulation of oral tranexamic acid is approved for treatment of cyclic heavy menstrual bleeding. MR tranexamic acid is initiated at the beginning of heavy menstrual bleeding and can be taken for up to 5 days per cycle. Clinical trials show it to be safe and effective. Dosage adjustments are needed for women with renal insufficiency. Adverse effects are considered mild to moderate, with the most common being menstrual discomfort, headache, and back pain. The most significant safety concerns relate to the risk of thromboembolism. CONCLUSIONS: MR tranexamic acid offers a new first-line therapy for patients with cyclic heavy menstrual bleeding. It is reported to be safe and effective. There are no labeled equivalents to MR tranexamic acid for cyclic heavy menstrual bleeding.

[1]  A. Waldbaum,et al.  Tranexamic acid increases hemoglobin and ferritin levels in women with heavy menstrual bleeding. , 2012, Journal of women's health.

[2]  J. Lavigne,et al.  Pharmacokinetic Studies in Women of 2 Novel Oral Formulations of Tranexamic Acid Therapy for Heavy Menstrual Bleeding , 2012, American journal of therapeutics.

[3]  A. Waldbaum,et al.  Long-Term Evaluation of Safety and Health-Related Quality of Life in Women with Heavy Menstrual Bleeding Treated with Oral Tranexamic Acid , 2011, Women's health.

[4]  E. Freeman,et al.  A dose-response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. , 2011, American journal of obstetrics and gynecology.

[5]  E. Freeman,et al.  Safety of Tranexamic Acid in Women with Heavy Menstrual Bleeding: An Open-Label Extension Study , 2011, Women's health.

[6]  P. Kouides,et al.  Tranexamic Acid: A Novel Oral Formulation for the Treatment of Heavy Menstrual Bleeding , 2011, Women's health.

[7]  D. Patrick,et al.  Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life , 2010, Current medical research and opinion.

[8]  H. Richter,et al.  Tranexamic Acid Treatment for Heavy Menstrual Bleeding: A Randomized Controlled Trial , 2010, Obstetrics and gynecology.

[9]  Daniel R. Brown,et al.  Antifibrinolytic therapy use to mitigate blood loss during staged complex major spine surgery: Postoperative visual color changes after tranexamic acid administration. , 2006, Anesthesiology.

[10]  A. Kriplani,et al.  Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate , 2006, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[11]  J. Bonnar,et al.  Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid , 1996, BMJ.

[12]  I. Cameron,et al.  Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia , 1995, British journal of obstetrics and gynaecology.

[13]  N. Gleeson Cyclic changes in endometrial tissue plasminogen activator and plasminogen activator inhibitor type 1 in women with normal menstruation and essential menorrhagia. , 1994, American journal of obstetrics and gynecology.

[14]  J. Bonnar,et al.  The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding , 1994, Acta obstetricia et gynecologica Scandinavica.

[15]  I. Milsom,et al.  A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. , 1991, American journal of obstetrics and gynecology.

[16]  J. Bonnar,et al.  The fibrinolytic enzyme system in normal menstruation and excessive uterine bleeding and the effect of tranexamic acid. , 1987, European journal of obstetrics, gynecology, and reproductive biology.

[17]  S. Smith,et al.  A ROLE FOR PROSTACYCLIN (PGI2) IN EXCESSIVE MENSTRUAL BLEEDING , 1981, The Lancet.

[18]  M. Iwamoto Plasminogen-Plasmin System IX. Specific Binding of Tranexamic Acid to Plasmin , 1975, Thrombosis and Haemostasis.

[19]  Y. Abiko,et al.  Plasminogen-plasmin system. V. A stoichiometric equilibrium complex of plasminogen and a synthetic inhibitor. , 1970, Biochimica et biophysica acta.

[20]  K. Wellington,et al.  Tranexamic Acid , 2012, Drugs.

[21]  J. Vessman,et al.  Pharmacokinetics and bioavailability of tranexamic acid , 2004, European Journal of Clinical Pharmacology.

[22]  ACOG practice bulletin: management of anovulatory bleeding. , 2001, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[23]  K. Goa,et al.  Tranexamic acid: a review of its use in surgery and other indications. , 1999, Drugs.

[24]  I. Nilsson Clinical pharmacology of aminocaproic and tranexamic acids , 1980, Journal of clinical pathology. Supplement.